ImmuCell Co. (NASDAQ:ICCC) Sees Large Growth in Short Interest

ImmuCell Co. (NASDAQ:ICCC) was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 2,000 shares, a growth of 33.3% from the June 30th total of 1,500 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the company’s stock are sold short.

ICCC stock traded down $0.12 during trading on Monday, reaching $5.80. The stock had a trading volume of 3,400 shares, compared to its average volume of 7,770. ImmuCell has a 1-year low of $5.55 and a 1-year high of $9.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.26 and a quick ratio of 6.25. The company has a fifty day moving average of $6.25.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Monday, May 13th. The biotechnology company reported $0.03 EPS for the quarter. ImmuCell had a negative net margin of 15.62% and a negative return on equity of 5.71%. The firm had revenue of $4.41 million for the quarter.

A hedge fund recently raised its stake in ImmuCell stock. Ingalls & Snyder LLC boosted its position in ImmuCell Co. (NASDAQ:ICCC) by 5.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,243 shares of the biotechnology company’s stock after buying an additional 4,732 shares during the quarter. Ingalls & Snyder LLC owned 1.33% of ImmuCell worth $626,000 at the end of the most recent quarter. 22.88% of the stock is currently owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

See Also: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.